109 related articles for article (PubMed ID: 28509576)
1. HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines.
Haghnavaz N; Asghari F; Elieh Ali Komi D; Shanehbandi D; Baradaran B; Kazemi T
Artif Cells Nanomed Biotechnol; 2018 May; 46(3):518-523. PubMed ID: 28509576
[TBL] [Abstract][Full Text] [Related]
2. Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.
Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
Adv Clin Exp Med; 2018 Jul; 27(7):941-945. PubMed ID: 30019863
[TBL] [Abstract][Full Text] [Related]
3. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
4. A novel report of MiR-4301 induces cell apoptosis by negatively regulating DRD2 expression in human breast cancer cells.
Gholipour N; Ohradanova-Repic A; Ahangari G
J Cell Biochem; 2018 Aug; 119(8):6408-6417. PubMed ID: 29236292
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
6. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
10. Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Wang W; Zhang L; Wang Y; Ding Y; Chen T; Wang Y; Wang H; Li Y; Duan K; Chen S; Yang Q; Chen C
Cell Death Dis; 2017 Oct; 8(10):e3071. PubMed ID: 28981108
[TBL] [Abstract][Full Text] [Related]
11. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes.
Papanikolaou V; Stefanou N; Dubos S; Papathanasiou I; Palianopoulou M; Valiakou V; Tsezou A
Cell Oncol (Dordr); 2015 Apr; 38(2):155-64. PubMed ID: 25539992
[TBL] [Abstract][Full Text] [Related]
12. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
13. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
Yang Q; Wang Y; Lu X; Zhao Z; Zhu L; Chen S; Wu Q; Chen C; Wang Z
Oncotarget; 2015 Feb; 6(5):3268-79. PubMed ID: 25605244
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Huynh FC; Jones FE
PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
[TBL] [Abstract][Full Text] [Related]
15. MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer.
Luo LJ; Yang F; Ding JJ; Yan DL; Wang DD; Yang SJ; Ding L; Li J; Chen D; Ma R; Wu JZ; Tang JH
Gene; 2016 Dec; 594(1):47-58. PubMed ID: 27593563
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
17. Decrease of let-7f in low-dose metronomic Paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer.
Tao WY; Liang XS; Liu Y; Wang CY; Pang D
Int J Biol Sci; 2015; 11(1):48-58. PubMed ID: 25552929
[TBL] [Abstract][Full Text] [Related]
18. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
[TBL] [Abstract][Full Text] [Related]
19. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
20. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
